GlassScriptPhysician profile
Rafiq Rahman
NPI 1598747099
$6,885.32
in general payments reported to CMS, 2019-2025
57 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $923 · 2021: $1,730 · 2022: $762 · 2023: $1,155 · 2024: $951 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.55 |
| Education | $181.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $843.28 | 2019-2024 | |
| Pfizer INC. | $566.03 | 2019-2025 | |
| Janssen Biotech, INC. | $441.92 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Daiichi Sankyo INC. | $337.27 | 2019-2025 | Enhertu, Datroway |
| Celgene Corporation | $336.93 | 2019-2024 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $320.97 | 2020-2025 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $281.78 | 2019-2024 | Tagrisso, Calquence |
| Seagen INC. | $270.48 | 2020-2022 | |
| Glaxosmithkline, LLC. | $247.26 | 2020-2025 | Zejula, Ojjaara |
| Incyte Corporation | $197.25 | 2020-2023 | Monjuvi, Jakafi |
| Lilly USA, LLC | $194.10 | 2019-2023 | Retevmo, Verzenio, Jaypirca |
| Amgen INC. | $169.56 | 2020-2023 | Lumakras |
| Astellas Pharma US INC | $167.67 | 2019-2024 | Padcev, Xospata |
| Kite Pharma, INC. | $157.36 | 2020-2024 | Yescarta |
| Abbvie INC. | $143.38 | 2021-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafiq Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.